Cadrenal Therapeutics, Inc.

Biotechnology · PONTE VEDRA, FL

BiotechnologySEC Form D

Cadrenal Therapeutics, Inc. filed a Form D with the U.S. Securities and Exchange Commission on April 6, 2026, reporting $7,923,235 raised.

Incorporated in Delaware and based in PONTE VEDRA, FL, it operates in the Biotechnology sector.

Companies file a Form D within 15 days of the first sale of securities in a private offering under Regulation D — an early, public signal that Cadrenal Therapeutics, Inc. has raised capital from private investors.

Browse more recently funded companies in Biotechnology.

Executives & Directors

  • Quang X. PhamExecutive Officer · Director
  • Matthew SzotExecutive Officer
  • James FergusonExecutive Officer
  • Jeffrey ColeExecutive Officer
  • John R. MurphyDirector
  • Steven ZelenkofskeDirector
  • Glynn WilsonDirector
  • Lee GoldenDirector

Recently funded in Biotechnology

Other companies that recently filed a Form D

$3.2MRaised

Goldenrod Therapeutics, Inc.

BiotechnologyHOUSTON, TX
May 26, 2026View SEC Form D
$10.0MRaised

Human Biotech, Inc.

BiotechnologyCAMBRIDGE, MA
May 22, 2026View SEC Form D
$1.0MRaised

Optimeos Life Sciences, Inc.

BiotechnologyPRINCETON, NJ
May 22, 2026View SEC Form D
$2.5MRaised

BioStem Technologies, Inc.

BiotechnologyPOMPANO BEACH, FL
May 21, 2026View SEC Form D
$10.0MRaised

Senti Biosciences Holdings, Inc.

BiotechnologySouth San Francisco, CA
May 20, 2026View SEC Form D
Cadrenal Therapeutics, Inc. raised $7.9M — SEC Form D